The importance of doxorubicin and methotrexate dose intensity in the chemotherapy of osteosarcoma

Arch Orthop Trauma Surg. 1996;115(2):68-70. doi: 10.1007/BF00573443.

Abstract

The relationship between dose intensity of cytotoxic agents and therapeutic results was examined in a retrospective analysis of 32 patients with non-metastatic high-grade osteosarcoma of the extremities. The average dose intensities of individual agents were 9.8 mg/m2/week for doxorubicin, 1.2 g/m2/week for methotrexate, and 10.5 mg/m2/week for cisplatinum. The dose intensities of doxorubicin and methotrexate were significantly correlated with the clinical results, while that of cisplatinum was not. These results indicate that maximal dose intensification of doxorubicin and methotrexate is an important determinant of treatment outcome for patients with osteosarcoma.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Antibiotics, Antineoplastic
  • Antimetabolites, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols* / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Bone Neoplasms / drug therapy*
  • Child
  • Child, Preschool
  • Disease-Free Survival
  • Dose-Response Relationship, Drug
  • Doxorubicin / administration & dosage
  • Doxorubicin / therapeutic use
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Methotrexate / administration & dosage
  • Methotrexate / therapeutic use
  • Middle Aged
  • Osteosarcoma / drug therapy*
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome

Substances

  • Antibiotics, Antineoplastic
  • Antimetabolites, Antineoplastic
  • Doxorubicin
  • Methotrexate